What the wildest week in AI means for medical sales
Nvidia's CEO resigned, Anthropic set its IPO, two flagship AI models shipped and Microsoft 365 went down. What it all means for medical sales leaders.
Key takeaways
- Jensen Huang resigned as CEO of Nvidia, the world's biggest AI chipmaker, on Nov. 11, 2026. CFO Colette Kress is interim CEO, and the company reports earnings today, Nov. 17.
- Anthropic, the maker of Claude, filed on Nov. 10 to sell 825 million shares at $70 to $78 each on the Nasdaq. Trading is expected to begin Nov. 19.
- Anthropic and Google each released a flagship AI model, on Nov. 9 and Nov. 10. An independent audit of Google's AI search summaries found about 11% of claims were not backed by the sources they cited.
- A Microsoft 365 outage cut most users off from Outlook for nearly 24 hours on Nov. 12 and 13.
Four AI stories broke in seven days, and each says something about where the technology is heading for commercial teams. The short version: the AI industry is maturing fast, general-purpose AI keeps improving without solving the problems specific to selling, and the advantage is shifting to teams that use AI built for their work.
Nvidia lost the only CEO it has ever had
Nvidia's board accepted Jensen Huang's resignation as president, CEO and director on Nov. 11, effective immediately, according to the company's SEC filing. Huang co-founded the company in 1993 and had led it ever since. CFO Colette Kress is interim CEO while the board searches for a successor. Shares fell 13% over the week, per CNBC, and Nvidia reports quarterly earnings today after the market closes.
What it means: Nvidia is the world's biggest AI chipmaker, so its earnings are the best single read on how much companies are investing in AI. A leadership change doesn't alter that demand, and it won't disrupt the AI products sales teams use. What it shows is how much of the industry rests on a few companies, which is one reason the AI market still moves in sudden steps.
Anthropic is about to go public
Anthropic filed on Nov. 10 to sell 825 million shares at $70 to $78 each on the Nasdaq under the ticker ANT, as reported from the filing. The filing also included a $26 billion investment at the IPO price from chip and cloud companies including Nvidia, Google and Microsoft, per a summary of the filing. CNBC's sources expect trading to start Nov. 19; Anthropic has not confirmed the date.
What it means: An offering of this size signals that investors now treat AI as lasting infrastructure, much as they came to treat cloud software. For commercial leaders, the question has moved from whether AI belongs in the sales organization to where it produces a measurable return. Pricing is still settling too: Google's introductory price for its newest model doubles after Nov. 30.
Two flagship models shipped, and the case for purpose-built AI got stronger
Anthropic released Claude Fable 5.2 and Mythos 5.2 on Nov. 9, and Google made Gemini 4 Carbon, which it calls its strongest model, generally available on Nov. 10. These upgrades reach everyone at once, including the physicians, practice managers and patients who use the same assistants to research treatments. What AI says about a product category can shift with each release.
Each generation writes and reasons better. None of them knows a sales team's world: the practices in a territory, what each one offers, or the claims a company has approved. And general AI still gets facts wrong with confidence. Researchers at Washington University in St. Louis checked 98,020 claims in Google's AI search summaries against the pages they cited. About 89% held up; the other 11% either weren't in the cited source or contradicted it.
That is why AI is splitting into two categories: general assistants that handle everyday writing and summarizing, and purpose-built AI designed around one job. A general assistant is built to answer anyone about anything, so what it knows about a given territory or customer is whatever the user supplies. Purpose-built AI starts from the other end. It typically runs on the same underlying models, but pairs them with data those models were never trained on and constrains them to the workflow of one profession. The value comes from that context: answers are grounded in current, domain-specific records, and the output arrives in the form the work requires. In medical sales, the work is specific: deciding which practices to call, researching each one, planning the visit and practicing the pitch. So are the pain points, for reps and for the leaders who manage them. Prospect Finder is one example of the category: AI built around those jobs and around selling to medical practices and the people who run them.
What it means: The productivity gains from AI in sales won't come from reps typing questions into a general chatbot. They come from AI that already understands the territory, the customer and the product, and that fits into how reps plan and prepare. A clear policy on general AI still matters (no patient or confidential information in consumer chatbots), but the larger opportunity is choosing where purpose-built AI can lift pipeline and close rates.
Microsoft 365 went down for most of a working day
A worldwide Microsoft 365 outage ran from 4:20 p.m. UTC on Nov. 12 to 4:10 p.m. UTC on Nov. 13, Microsoft said in its preliminary incident report, as reported by Cybersecurity News. Most users couldn't reach their mailboxes through Outlook, and Teams, SharePoint and Microsoft's Copilot AI assistant were also disrupted. Microsoft traced it to a Windows bug that overwhelmed the servers handling cloud connections.
What it means: Email, calendars and now AI assistants increasingly run through a single vendor, so one failure can stall a field team for a day. As AI takes on more of the selling workflow, resilience belongs in the buying decision alongside features and price.
The bottom line
Last week showed an AI industry that is consolidating, well funded and still volatile. The models will keep improving on their own schedule. What sales leaders control is how their teams apply AI, and the evidence points toward AI built for the specifics of medical selling: knowing the practice before the meeting, and rehearsing the conversation before it counts.